Analysts Set argenex SE (NASDAQ:ARGX) Price Target at $999.22

Shares of argenex SE (NASDAQ:ARGX) have been given a consensus recommendation of “Moderate Buy” by the twenty-three research firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $999.2222.

A number of analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Guggenheim reduced their price target on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. DZ Bank raised shares of argenex to a “strong-buy” rating in a research note on Friday, December 19th. Citizens Jmp boosted their price objective on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Finally, Citigroup cut their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th.

Institutional Trading of argenex

Several institutional investors have recently added to or reduced their stakes in ARGX. Abound Wealth Management increased its holdings in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after buying an additional 32 shares during the period. Sound Income Strategies LLC purchased a new stake in argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. bought a new position in argenex during the 3rd quarter worth approximately $32,000. Aventura Private Wealth LLC bought a new position in argenex during the 4th quarter worth approximately $38,000. Finally, Sunbelt Securities Inc. purchased a new position in argenex in the 3rd quarter worth approximately $36,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Stock Down 3.0%

NASDAQ ARGX opened at $663.93 on Wednesday. The stock’s 50-day simple moving average is $792.62 and its two-hundred day simple moving average is $816.68. argenex has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market capitalization of $41.08 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 1.10 and a beta of 0.38.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, equities analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.